Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group b streptococcus
AssigneeIntelligent Medical Devices, Inc.
InventorsDamien Slater, Chesley Leslin, Juan Anzola, David Dolinger, Alice A. Jacobs
Life of this patent
Estimating the term…
Abstract
Described herein are oligonucleotides useful for detecting, isolating, amplifying, quantitating, monitoring, screening and sequencing GBS genes and methods of using the described oligonucleotides.
Claims51
An isolated nucleic acid sequence comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 1-64.
A method of hybridizing one or more isolated nucleic acid sequences comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 1-35 to a GBS sequence, comprising contacting one or more isolated nucleic acid sequences to a sample comprising the GBS sequence under conditions suitable for hybridization.
A primer set comprising at least one forward primer selected from the group consisting of SEQ ID NOS:
- 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33, and at least one reverse primer selected from the group consisting of SEQ ID NOS:
- 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.
A method of producing a nucleic acid product, comprising contacting one or more isolated nucleic acid sequences selected from the group consisting of SEQ ID NOS:
- 1, 3, 4, 6, 7, 8, 10, 11, 13, 14, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 32, 33 and 35 to a sample comprising a GBS sequence under conditions suitable for nucleic acid polymerization.
A method for detecting a GBS sequence in a sample, comprising:
- a) contacting the sample with at least one forward primer comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33, and at least one reverse primer comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35 under conditions such that nucleic acid amplification occurs to yield an amplicon;
- and
- b) contacting the amplicon with one or more probes comprising one or more sequences selected from the group consisting of:
- SEQ ID NOS:
- 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions such that hybridization of the probe to the amplicon occurs;
- wherein hybridization of the probe is indicative of GBS in the sample.
A kit for detecting a GBS sequence in a sample, comprising one or more probes comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34.
A method of diagnosing a GBS-associated colonization, condition, syndrome or disease, comprising:
- a) contacting a sample with at least one forward and reverse primer set selected from the group consisting of:
- Groups 1-13 of Table 2;
- b) conducting an amplification reaction, thereby producing an amplicon;
- and
- c) detecting the amplicon using one or more probes selected from the group consisting of:
- SEQ ID NOS:
- 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34;
- wherein the detection of an amplicon is indicative of the presence of GBS in the sample.
A kit for binding, amplifying and sequencing a GBS sequence in a sample, comprising:
- a) at least one forward primer comprising the sequence selected from the group consisting of:
- SEQ ID NOS:
- 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33;
- and
- b) at least one reverse primer comprising the sequence selected from the group consisting of:
- SEQ ID NOS:
- 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35;
- and
- c) reagents for the sequencing of amplified DNA fragments.
A method of diagnosing a GBS-associated colonization, condition, syndrome or disease, comprising contacting a denatured target from a sample with one or more probes comprising a sequence selected from the group consisting of:
- SEQ ID NOS:
- 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions for hybridization to occur;
- wherein hybridization of the one or more probes to a denatured target is indicative of the presence of GBS in the sample.
A method for identifying the causative agent of early-onset and/or late-onset disease in infants by detecting one or more GBS strains in a sample based on its gene(s), the method comprising:
- a) contacting the sample with at least one forward primer comprising the sequence selected from the group consisting of:
- SEQ ID NOS:
- 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33 and at least one reverse primer selected from the group consisting of SEQ ID NOS:
- 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35 under conditions such that nucleic acid amplification occurs to yield an amplicon;
- and
- b) contacting the amplicon with one or more probes comprising one or more sequences selected from the group consisting of:
- SEQ ID NOS:
- 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions such that hybridization of the probe to the amplicon occurs;
- wherein the hybridization of the probe is indicative of GBS in the sample.
A screening kit for binding and amplifying a GBS sequence, comprising:
- a) at least one forward primer comprising the sequence selected from the group consisting of:
- SEQ ID NOS:
- 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33;
- and
- b) at least one reverse primer comprising the sequence selected from the group consisting of:
- SEQ ID NOS:
- 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.
Dependencies are inferred from the claim text.